Come Flood Or High Water – How BioNet Is Shaping Its Vaccine Ambitions
Executive Summary
Emerging Company Profile: Thailand-based BioNet stuck it out despite widespread flooding at its site and now expects to take its pertussis vaccine to key Western markets.
You may also be interested in...
India’s ‘Cautious’ View Dulls Sanofi Hopes For Early Dengvaxia Launch
An early rollout of Sanofi Pasteur’s dengue vaccine in India is looking less likely with a senior functionary of the health ministry telling Scrip why India needs to take a “cautious view” on the product’s licensure in the country, at least for now. Sanofi, though, has sought the “best regulatory solution” that can facilitate access to the product.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet